Date: 2014-11-11
Type of information: Nomination
Compound:
Company: Innate Immunotherapeutics (Australia)
Therapeutic area: Autoimmune diseases - Neurodegenerative diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On November 11, 2014, Innate Immunotherapeutics announced that the companu has appointed Dr Claudia Mansell as Senior Research Scientist to lead the analysis of trial subjects' blood samples. The goal of this work is to develop tests that could be used to help monitor patients' responses to treatment with MIS416. Developing such a test would be a significant achievement as there are currently no blood tests available to monitor the effects of disease or treatment in patients with SPMS.
Dr Mansell obtained her Ph.D. in Immunology at the Heinrich Heine Universität (Düsseldorf, Germany) and the Harvard Medical School (Boston) and has joined the Company from the School of Biological Sciences, University of Auckland.
Financial terms:
Latest news:
Is general: Yes
